Encruse Ellipta approved in Japan

According to GSK, the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved its Encruse Ellipta umeclidinium DPI for the treatment of COPD, and the company plans to launch the product in Japan sometime this year. The approved dosage is 62.5 mcg. GSK announced in May 2014 that it had filed the application for . . . Read more

Invion announces successful pre-IND meeting with FDA for inhaled nadolol

According to Invion Limited, the company “has received a positive response” from the FDA during a pre-IND meeting regarding its INV102 inhaled nadolol for the treatment of asthma and COPD. Invion is developing the drug in partnership with 3M Drug Delivery Systems, and the company said that the agency has accepted both the formulation and . . . Read more

Verona says interim results from Phase 1/2 study of RPL554 look promising

Verona Pharma has announced what it calls “encouraging interim results” from a Phase 1/2 study of a new formulation of its RPL554 PDE3/4 inhibitor for the treatment of COPD exacerbations. The company had announced the initiation of the 120-subject study of the nebulized formulation in January 2015 and now says that the trial is ahead . . . Read more